Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
Discover how coincident indicators reflect current economic conditions, their role in analyzing business cycles, and their impact on understanding economic trends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results